CliffBio
small molecule

CASPOFUNGIN ACETATE

CASPOFUNGIN ACETATE

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameCASPOFUNGIN ACETATE
Active ingredientCASPOFUNGIN ACETATE
Strength70MG/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJuly 2018
Marketing statusDISCN

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

CASPOFUNGIN ACETATE patent cliff — loss of exclusivity — | CliffBio